Translated title of the contribution: New perspectives in the treatment of VZV-infections

R. Engst

Research output: Contribution to journalShort surveypeer-review


The varicella-zoster virus (VZV) causes the exanthematous illnesses varicella and herpes zoster. For the treatment of bacterial infections various antibiotics have been available for decades, however, the possilibity to treat virus infections such as varicella-zoster has only existed for a few years. Currently, the primary antiviral therapy for VZV-infections is acyclovir. With the development of new VZV-active virostatic agents which are showing advantages in the pharmacokinetic and antiviral characteristics over acyclovir, alternative drugs are now available or will be available in the near future with special attention to the orally administered new virostatic drugs famciclovir and brivudin. The following overview summarizes virologic, pharmacokinetics and clinical data for these 2 substances and give a short preview of further agents with VZV-activity which are currently in the clinical trial phase.

Translated title of the contributionNew perspectives in the treatment of VZV-infections
Original languageGerman
Pages (from-to)111-112+114+120
JournalTW Gynakologie
Issue number2
StatePublished - 1995
Externally publishedYes


Dive into the research topics of 'New perspectives in the treatment of VZV-infections'. Together they form a unique fingerprint.

Cite this